Tudorza Pressair (TU-door-za, aclidinium), a new inhaled anticholinergic for COPD

December 2012

Reps will promote Tudorza Pressair (TU-door-za, aclidinium), a new inhaled anticholinergic for COPD.

It's an alternative to tiotropium (Spiriva) for maintenance treatment of COPD bronchospasm.

Aclidinium is a bronchodilator comparable to tiotropium.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology whether ALL patients with coronary artery disease should take a beta-blocker
Anticoagulants Xarelto (rivaroxaban) will be used to TREAT venous thromboembolism
Anticoagulants more about bleeding with Pradaxa (dabigatran)
Gastroenterology Linzess (lin-ZESS, linaclotide) for irritable bowel syndrome with constipation or chronic constipation in adults
Vaccines Prevnar 13 vaccine will be used in certain ADULTS
Vaccines New CDC recommendations will bring more focus on proper vaccine storage
Corticosteroids Rayos, a new delayed-release prednisone that's designed for evening dosing
Diabetes debate about whether diabetes patients who don't use insulin benefit from monitoring their blood glucose
Respiratory & Allergy Tudorza Pressair (TU-door-za, aclidinium), a new inhaled anticholinergic for COPD
Gout rev up promotion of Uloric (febuxostat) for managing gout
Compounding new oversight of pharmacy compounding
Interactions PPIs with methotrexate can lead to methotrexate toxicity
Practice we hope you'll enjoy the holiday letter from our staff